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ABSTRACT 
 Obesity has emerged as a leading environmental risk factor for the development 
of CRC.  However, the mechanisms underlying this relationship have not yet been fully 
explained.  Recent literature has focused on 1) inflammatory processes, 2) adipokines, 
and 3) estrogen.  Obesity-enhanced inflammation is largely orchestrated by increases in 
adipose tissue macrophages leading to the secretion of TNF-α, MCP-1, and IL-6, all of 
which are linked to CRC.  Adiponectin is decreased with obesity and has been reported to 
be negatively associated with CRC, while leptin, which is increased, is positively 
associated with the disease.  Estrogen has been shown to influence CRC, although its role 
remains controversial; some studies have implicated estrogen as being protective, while 
others have suggested it to be a risk factor.  We highlight the most important recent 
advances that have been made on the aforementioned mechanisms that are thought to link 
obesity to CRC.      
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CHAPTER 1 
INTRODUCTION 
Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in 
the United States. Overall survival is highly dependent on disease stage at diagnosis, with 
the estimated 5-year survival rates range from 85% to 90% for patients with stage I 
disease to <5% for patients with stage IV disease.  The etiology of CRC is complex and 
involves the interaction of genetic and environmental factors.  However, the vast majority 
of cases can be attributed to environmental causes as they account for >70% of all 
incidences 30.  Recently, obesity has emerged as a leading environmental risk factor for 
CRC 29,37,48,49.  In fact, a 5 kg/m2 increase in body mass index (BMI) has been positively 
associated with CRC risk48.  Due to the excessive availability of energy dense food and 
lack of physical activity, obesity levels have risen dramatically in the United States42.  
Indeed, the prevalence of obesity, defined by a BMI >30 kg/m2, has now reached 35% 
with no indication of a decline42,18. While there is an abundance of data to support a link 
between obesity and CRC risk, the mechanisms responsible for this relationship have not 
yet been fully elucidated and are likely mediated by a complex network of biochemically 
and immunologically factors produced by adipose tissue.  This review will examine the 
recent literature on the possible mechanisms linking obesity to CRC, with emphasis on 
the most recent literature and is not intended to be a comprehensive review.  
.
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CHAPTER 2 
INFLAMMATION 
Inflammation has been linked to every event in the development and progression of CRC 
including cellular transformation, promotion, survival, proliferation, invasion, 
angiogenesis, and metastasis23,49,6,15.  Furthermore, it is well established that 
inflammatory bowel diseases, including Crohn’s disease and ulcerative coloitis, are 
linked to an increased risk for the development of CRC. Given that obesity is now 
considered a low-grade inflammatory condition, a likely pathophysiological mechanism 
that links obesity to CRC risk is chronic inflammation.    
2.1 MACROPHAGES 
Obesity-induced inflammation is largely mediated through quantitative and functional 
alterations in white adipose tissue macrophages56,36,20.  It has been reported that 
approximately 45-60% of adipose tissue cells express the macrophage marker EMR1 
(F4/80) in obese mice, whereas only 10-15% of adipose tissue cells from lean mice 
express this marker56.  In addition, adipose tissue macrophages exhibit a pro-
inflammatory, classical phenotype (M1) in obese mice, while those from lean mice have 
an alternatively-activated, anti-inflammatory phenotype (M2)36.  We recently reported 
that a high fat diet, closely mimicking the macronutrient content of the American 
standard diet, can lead to increased obesity that is associated with pro-inflammatory 
macrophage behavior14.  Given the propensity for adipose tissue macrophages to assume 
an inflammatory phenotype and the well-characterized link between inflammation and 
CRC, it is likely that macrophages play a necessary role in the link between obesity and 
CRC.  However, no studies have used manipulation techniques to directly determine the 
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role of adipose tissue macrophages in the progression of this disease. Nonetheless, the 
current evidence for a necessary role of macrophage-induced inflammatory mediators, 
which are known to activate pathways that can promote CRC, is relatively strong.  
2.2 TUMOR NECROSIS FACTOR-ALPHA 
Following excessive lipid accumulation, tumor necrosis factor alpha (TNF-α) is 
produced by adipose tissue macrophages and also to a lesser degree by adipocytes and 
preadipocytes.  Although elevated TNF-α has been widely documented in adipose tissue 
with obesity, data on obesity-associated TNF-α in the colon is just now beginning to 
appear in the literature.   Liu et al., reported a >70% increase in expression and 
concentration of TNF-α in the colon following 17 weeks of high fat diet feedings, which 
was associated with an increase in β-catenin, the key effector of Wnt signaling35.   In 
addition, an elegant study by Flores et al., examined the role of TNF-α on obesity-
induced CRC in mice19. They reported that high fat diet feeding increased TNF-α 
expression in the colon that was associated with a larger number of tumors, increased 
proliferation, and decreased apoptosis19.  When TNF-α was inhibited, these effects were 
reversed; inhibition of TNF-α restored tumor number and the apoptosis/proliferation 
profile to levels observed in a lean mouse19.  A recent clinical study examined TNF-α, 
among other cytokines, in rectosigmoid mucosal biopsies of 10 obese premenopausal 
women before and after weight loss47.  Weight loss (10%) was associated with a 
significant decrease in TNF-α concentration indicating a reduction in colorectal 
inflammation47. However, another study reported no change in circulating levels of TNF-
α in obese patients or CRC patients compared to controls26.  Similarly, there was no 
relationship reported between BMI and circulating TNF-α and risk for CRC in colorectal 
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adenoma patients28.  Although the clinical evidence is relatively limited, the recent 
controlled experimental studies in rodents support a role of TNF-α in obesity-enhanced 
CRC.   
2.3 MONOCYTE CHEMOATTRACTANT PROTEIN-1 
Monocyte chemoattractant protein 1 (MCP-1) has been identified as an essential 
chemokine for monocyte trafficking.  It has been reported to contribute to tissue 
macrophage accumulation by inducing a chronic inflammatory state.  A recent 
investigation transferred wild-type monocytes to MCP-1-/- recipients and reported that 
adipose tissue macrophage accumulation was reduced by ~40%, implicating the MCP-1 
system as a major contributory factor to monocyte migration into adipose tissue43.  
Incidentally, it has also been implicated as an important chemokine for macrophage 
recruitment in several human tumors including CRC and has been associated with 
increased grade of the tumor as well as poor prognosis45,58.  McClellan et al.  recently 
reported an increase in MCP-1 in intestinal tissue in a mouse model of CRC that was 
positively correlated with the percentage of large polyps38. Subsequently, they crossed 
the ApcMin/+ mouse model of intestinal tumorigenesis with an MCP-1-/- mouse to examine 
the role of this chemokine in CRC39.  MCP-1 deficiency decreased overall polyp number 
as well as large polyp number39.  Further, macrophage positive cells were decreased in 
the polyp tissue as well as expression of markers associated with M1& M2 macrophages 
as well as T regulatory cells , while markers for cytotoxic T cells were increased39.  In 
addition, MCP-1-/- offset the increased expression of inflammatory mediators in polyp 
tissue39.  Similarly, Bailey et al. has reported that MCP-1 expression is associated with 
tumor associated macrophage number and stage of CRC in humans7 and recently, 
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Hilenbrand et al., reported that circulating MCP-1 was increased in both obese patients 
and CRC patients26.   Conversely, a recent report showed lower MCP-1 levels in CRC 
patients compared to controls30.   Although there have been no studies that have 
specifically examined the role of MCP-1 in obesity-enhanced CRC, the evidence in the 
independent models largely support a disease-promoting effect of MCP-1 in both obesity 
and CRC.  
2.4 IINTERLEUKIN-6    
Interleukin (IL)-6, an inflammatory cytokine released by adipocytes and adipose 
tissue macrophages during obesity11, may play a role in obesity-enhanced CRC21. In fact, 
epidemiological studies indicate an association between IL-6 and CRC and controlled 
experiments in mice substantiate these claims55,24.  For example, Baltgalvis et al., 
reported that IL-6 deficiency reduced the number of large polyps by approximately 30% 
in the ApcMin/+ mouse, the effects of which were reversed when IL-6 was overexpressed8.  
A recent clinical study reported that IL-6 expression is a prognostic marker of tumor 
behavior in stage III CRC patients32.   Similarly, high levels of circulating IL-6 have been 
found to be associated with advanced CRCs30.  Furthermore, in individuals with 
adenoma, levels of IL-6 were positively correlated with BMI, insulin and insulin 
resistance52.  The mechanisms for IL-6-induced tumorigenesis are thought to be 
mediated, at least in part, via activation of signal transducers and activators of 
transcription 3 (STAT3).  A recent report documented increased IL6 and p-STAT3-
positive epithelial cells in patients with active ulcerative colitis compared to patients with 
inactive ulcerative colitis or controls33 and in dysplasia and CRC, significantly more 
epithelial cells expressed IL6 and p-STAT3 compared with controls33.   To our 
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knowledge there are no studies that have specifically examined the role of IL-6 on CRC 
in an obesity setting.  However, it is clear that IL-6, which is increased with obesity, can 
influence CRC.    
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CHAPTER 3 
ADIPOKINES 
In addition to their traditional role in energy homeostasis, adipose-derived hormones 
(adipokines) have been implicated as potential mediators of the effects of obesity on CRC 
risk. Adiponectin and leptin, two of the most abundant adipokines, are altered during 
adipose tissue dysfunction (i.e. obesity) and have been strongly associated with the 
pathogenesis of CRC.   
3.1 ADIPONECTIN 
Adiponectin, an adipokine secreted exclusively by adipose tissue, is decreased in 
obese subjects, likely increasing their propensity for the development of CRC. Several 
recent mechanistic studies using mice have made substantial advancements in our 
understanding of the role of adiponectin in CRC. For example, Saxena et al. examined 
the effect of adiponectin deficiency on chronic inflammation-induced CRC53.  They 
reported that deficiency of adiponectin results in more severe symptoms along with a 
greater number and larger area of tumors that included higher immune cell infiltration 
and inflammation compared to wild-type mice53.  Adiponectin knockout mice also 
showed higher secretion of the pro-inflammatory cytokines including IL-6, IL-1β, and 
TNF-α and a reduction in the anti-inflammatory cytokine IL-1053. The concluded that 
APN deficiency plays an important role in contributing to inflammation-induced colon 
cancer due to the increased severity of symptoms, the up-regulation of pro-cancerous and 
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downregulation of anti-cancerous and inflammatory genes, and the absence of APN-
induced downregulation of secretion of pro-inflammatory cytokines.  Similarly, a recent 
study by Moon et al. precisely examined the role of adiponectin on CRC in the settings of 
obesity40.  They found that mice fed a high fat diet had larger tumors than those fed a low 
fat diet but adiponectin administration reversed this effect40.  Adiponectin treatment also 
suppressed angiogenesis in tumors as indicated by fewer dense microvessel areas and a 
reduction in mRNA expression of VEGF40.  While IL-12, a cytokine that has been 
associated with anti-tumor properties was increased following adiponectin treatment, in 
contrast to the findings of Saxena et al., serum cytokine (IFN-γ, IL-2, IL-4, IL-5, IL-10 
and TNF-α) levels were unchanged40. To further address the mechanisms for this effect 
they completed a series of in vitro studies and found that adiponectin directly controls 
malignant potential (cell proliferation, adhesion, invasion and colony formation) and 
regulates metabolic (AMPK/S6), inﬂammatory (STAT3/VEGF) and cell cycle 
(p21/p27/p53/cyclins) signaling pathways in both mouse and human colon cancer cells 
lines40. These results highlight the importance of adiponectin in the growth and 
development of CRC, inflammatory processes, and suggest that the adiponectin 
deficiency that is a characteristic of obesity plays an important role in the biochemistry of 
CRC. 
Consistent with the animal literature, clinical studies also support a potential role for 
adiponectin in the link between obesity and CRC.  A recent study reported a decrease in 
serum adiponectin levels in CRC patients compared to controls as well as a negative 
correlation between adiponectin levels and stage of disease22.  In contrast to Hillenbrand 
et al., which reported a decrease in adiponectin in obese patients, the levels reported for 
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CRC patients were not different from the control samples26.  These conflicting findings 
may be result from the lack of differentiation of adiponectin fractions in these studies; 
adiponectin fractions are hypothesized to have different biological activities (i.e. high 
molecular weight (HMW) adiponectin is thought to regulate insulin sensitivity whereas 
non-HMW adiponectin plays a role in the inflammatory response).  In support of this 
hypothesis, Aleksandrova et al. reported that total adiponectin and non-HMW 
adiponectin concentrations were inversely associated with risk of CRC but there was no 
association for HMW adiponectin3.  While the animal studies support a role of 
adiponectin in CRC, investigation of the relative importance of different adiponectin 
fractions in CRC pathogenesis is necessary prior to the development of effective clinical 
therapeutic strategies.     
3.2 LEPTIN  
Most studies have found that leptin levels increase in direct proportion to body fat 
and thus are elevated in obese individuals. The results from research on the effect of 
leptin on CRC risk are contradictory. While there is an abundance of literature to 
implicate leptin as a potential mediator between obesity and CRC, the exact mechanisms 
have not yet been elucidated, which is not surprising given the inconsistencies in the 
literature.  In some studies, elevated serum leptin levels were associated with a more 
positive clinical outcome46, including overexpression of the long-form signaling receptor, 
ObRb, which may allow leptin to activate inﬂammatory genes4,54 and stimulate 
inﬂammatory responses in tumour colonocytes, leading to recruitment of cytotoxic T-
cells within the tumor microenvironment1. In other studies, decreased serum leptin levels 
were found in CRC patients9. Nonetheless, recent studies have advanced our 
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understanding of the role of this adipokine in CRC.  The proposed link between leptin 
and CRC was driven initially by reports of leptin receptor expression by various human 
epithelial colon cancer cell lines. When bound to leptin, the receptor can activate signal 
transduction pathways that are thought to enhance cell proliferation and DNA synthesis.   
For example, Fenton et al., reported that leptin promotes the proliferation of preneoplastic 
(IMCE) cells17. While the in vitro evidence is relatively strong, there are mixed reports 
among the animal studies.   For instance, an earlier study reported that leptin failed to 
promote growth of colon cancer xenografts in nude mice and did not increase intestinal 
tumorigenesis in ApcMin/+ mice5.  In contrast, a more recent study found a significant 
decrease of tumor cell proliferation in leptin-deficient tumors, as well as a dramatic 
inhibition of tumor growth in leptin-deficient and leptin-receptor-deficient mice despite 
the animals exhibiting severe obesity13.  This ability of leptin to regulate CRC growth 
was mediated by colonic leptin signaling via the leptin receptor/signal transducer and 
activator of transcription 3 (STAT3) pathway, suggesting that leptin signaling is a direct 
pathway that is critical for CRC growth and not merely a bystander of the established 
relationship between obesity and CRC13.   
Although clinical investigations have provided evidence for a link between leptin 
and CRC, like the animal studies, there are some inconsistencies among findings.  A 
recent study by Aleksandrova et al. examined the association of leptin and soluble leptin 
receptor, which has been found to regulate leptin’s physiologic functions, with the risk of 
CRC in a prospective nested case-control study2.  They reported that soluble leptin 
receptor was strongly and inversely associated with CRC risk but there was no 
association found for leptin and CRC risk2.  And in fact, another study reported that 
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leptin concentrations were actually decreased in CRC patients26.   In contrast, in a case-
cohort study design, it was found that leptin has an independent effect on CRC in post-
menopausal women27.  Based on the recent literature it is likely that leptin plays a 
significant role in CRC; however, additional studies are needed to confirm this 
relationship and to clarify the exact mechanisms underlying these effects.    
3.3 ESTROGEN 
 Estrogen is increased with obesity and has been shown to influence CRC, 
although its role remains controversial. While some studies have implicated estrogen as 
being protective in CRC, others have suggested it to be an independent risk factor. Recent 
evidence favors a protective effect of estrogen receptor-β (Erβ).  For example, a greater 
number of tumors and an increased inflammatory response were documented in Erβ 
deficient mice51. Also, Erβ expression has also been shown to increase apoptosis, 
downregulate IL-6, increase repair of DNA damage, and change gene transcription12. 
ERα has been associated with an increase colon cancer cell proliferation and increase 
cancer incidence. For example, it was reported that ovariectomy protects female mice 
against colitis associated CRC, while estrogen replacement promotes inflammation and 
tumor development25.  Chen and Iverson hypothesize that the variation in results among 
these previous studies may be due to estrogen acting through two different estrogen 
receptors (ERα and ERβ)10. Further, the pro-tumorigenic effects were found to be 
dependent on both Erα and Erβ25.   The clinical literature largely supports a protective 
effect of estrogen; a recent study reported that lack of Erβ expression in tumors was 
associated with higher cancer stages as well as greater tumor extent50.  Further, Erβ 
negativity was associated with an increased hazard ratio for death, death attributed to 
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CRC, as well as a poorer disease-free survival.  Consistently, Fang et al. reported that low 
expression of tumor Erβ is a risk factor for overall survival in patients with stage II colon 
cancer16 and postmenopausal hormone therapy is associated with reduced risk of CRC54.  
An interesting finding from a study by Yi KW et al. showed that ERα agonist increased 
adipocyte production of leptin while ERα antagonist decreased leptin production57. The 
effect of ERβ agonists was the opposite in that they lead to decreased leptin production, 
while ERβ antagonists increase leptin production57. In contrast, ERs were not associated 
with changes of other adipokines examined in this study, including adiponectin57. These 
ﬁndings are consistent with a recent study, which showed that Erβ agonist silibinin 
decreased leptin41. The effect that obesity has on this relationship remains elusive due to 
its different actions through two different receptor subtypes. In general, the current 
evidence supports a protective effect of estrogen, and specifically Erβ, in CRC. However, 
the exact mechanisms have not yet been determined.  
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CHAPTER 4 
CONCLUSION 
The development of the majority of CRCs is largely influenced by non-genetic factors 
such as obesity. Therefore, a large body of research is now focused on understanding the 
molecular links between obesity and CRC.  While inflammatory mediators, adipokines, 
and estrogen have all been implicated as causative agents, there have been some 
inconsistencies in the literature and there is a shortage of evidence in the setting of 
obesity.  Future studies should explore these mechanisms specifically in obesity models.  
And further, should examine interactions between these factors as it is likely that this 
relationship is mediated by a complex network of interrelated mechanisms. 
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